TICKERNERD
Menu
COLLCOLLHealthcare · Drug Manufacturers - Specialty & Generic

COLL Stock Forecast: Collegium Pharmaceutical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$27
−1.56% on the day

The 5 Wall Street analysts covering Collegium Pharmaceutical, Inc. hold a median 12-month price target of $48 — +77.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 21 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$893.2M
Ticker Nerd rank
80 / 100
Median analyst target
$48
Analysts covering
5
Total return, dividends reinvested
1W
−4.0%
1M
−24.4%
YTD
−41.4%
1Y
−31.4%
From 52W high
−45.6%
From 52W low
+5.5%
$26
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COLL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Collegium Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
95
Volatility
92
Growth
86
Accruals
64
Size
47
Momentum
45
Revisions
39
Issuance
31

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COLL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COLL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60Oct 25Jan 26Apr 26Jul 26COLLHigh $60Median $48Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $43Median $48High $60

The green dot is the last close — the median target sits +77.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Piper SandlerReiteratesNeutral$45 → $43
6 Aug 2026NeedhamMaintainsBuy$56 → $46
20 Mar 2026HC Wainwright & Co.ReiteratesBuy$60
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026NeedhamReiteratesBuy—
19 Mar 2026NeedhamReiteratesBuy$54 → $56
26 Feb 2026NeedhamMaintainsBuy—
9 Jan 2026BarclaysMaintainsOverweight—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
8 Jan 2026NeedhamMaintainsBuy—
9 Dec 2025BarclaysInitiatesOverweight—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2025Truist SecuritiesMaintainsBuy—
28 Oct 2025NeedhamReiteratesBuy—
11 Aug 2025HC Wainwright & Co.AssumesBuy$44
9 May 2025Piper SandlerReiteratesNeutral—
9 Apr 2025NeedhamReiteratesBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
4 Feb 2025Piper SandlerMaintainsNeutral—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COLL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

COLL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.0%
Analysts raising
0
Analysts cutting
2
Fundamentals

Collegium Pharmaceutical, Inc. (COLL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.8×

Cheaper than 35% of US stocks

Price / sales
1.1×

Cheaper than 69% of US stocks

Price / book
2.9×

Cheaper than 36% of US stocks

EV / EBITDA
4.9×

Cheaper than 53% of US stocks

Growth & margins
Revenue growth (YoY)
6.3%

Higher than 42% of US stocks

Earnings growth (YoY)
6.3%

Higher than 43% of US stocks

Gross margin
55.2%

Higher than 68% of US stocks

Operating margin
5.7%

Higher than 56% of US stocks

Net margin
5.9%

Higher than 62% of US stocks

Returns & dividend
Return on equity
17.6%

Higher than 78% of US stocks

Return on assets
5.8%

Higher than 80% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

COLL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
COLLCollegium Pharmaceutical, Inc.$893.2M
80
GLASGlass House Brands, Inc.$810.6M
45
AMPHAmphastar Pharmaceuticals, Inc.$952.4M
85
PCRXPacira Biosciences, Inc.$998.9M
99
IRWDIronwood Pharmaceuticals, Inc.$699.5M
100
TLRYTilray Brands, Inc.$659.2M
18
AQSTAquestive Therapeutics, Inc.$584.9M
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Collegium Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COLL news & analysis

Collegium Announces $50 Million Accelerated Share Repurchase Program

GlobeNewsWire · 13 Aug 2026positive

Collegium Pharmaceutical announced it entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Following completion, $100 million will remain under the program.

Why it matters — The buyback signals the company's ongoing capital-return activity under its authorized repurchase program, which may be of interest to stockholders tracking share count and capital allocation.

Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Collegium Pharmaceutical, Inc.'s Q2 2026 earnings call. The content consists of the call's headline and transcript listing with no additional detail provided.

Why it matters — A COLL watcher would care because the transcript represents the company's official second-quarter earnings call communication.

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 6 Aug 2026neutral

Collegium Pharmaceutical reported its earnings for the quarter ended June 2026. The article examines how the company's revenue, EPS, and other key metrics compare with Wall Street estimates and year-ago figures.

Why it matters — A COLL watcher would care because this review shows how the company's actual quarterly performance stacked up against analyst expectations and prior-year results.

Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Collegium Pharmaceutical reported Q2 earnings of $1.92 per share, surpassing the Zacks Consensus Estimate of $1.68 per share. This matches the earnings per share of $1.68 recorded in the same quarter a year ago.

Why it matters — A COLL watcher would note that the company exceeded analyst earnings expectations for the quarter, indicating stronger-than-anticipated performance.

Collegium Pharmaceutical Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

Collegium Pharmaceutical reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier. Growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise.

Why it matters — The revenue mix showing gains in ADHD and BELBUCA partially offsetting NUCYNTA's decline highlights how Collegium's product portfolio is shifting for investors tracking the company.

FAQ

Frequently asked questions about COLL stock

What is the COLL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Collegium Pharmaceutical, Inc. have a median 12-month price target of $48, with estimates ranging from $43 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COLL stock a buy right now?

Of the 5 analysts covering Collegium Pharmaceutical, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Collegium Pharmaceutical, Inc. 80 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COLL?

As at 21 Aug 2026, Collegium Pharmaceutical, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will COLL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +77.1% from the last close, and Ticker Nerd's factor model ranks Collegium Pharmaceutical, Inc. 80 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COLL stock forecast for 2030?

No analyst covering Collegium Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $60 over the next 12 months.

How has COLL stock performed over the past year?

Collegium Pharmaceutical, Inc. returned -31.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Collegium Pharmaceutical, Inc. do?

Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone.

What is the latest news on COLL?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Collegium Announces $50 Million Accelerated Share Repurchase Program". Collegium Pharmaceutical announced it entered into an Accelerated Share Repurchase agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Following completion, $100 million will remain under the program.

Company

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical is a specialty biopharmaceutical company focused on developing and commercializing medicines for pain management and neuropsychiatric conditions. The company's primary portfolio includes Jornay PM, a central nervous system stimulant for attention deficit hyperactivity disorder; Belbuca, a buccal film containing buprenorphine for chronic pain; and Xtampza ER, an abuse-deterrent extended-release oral formulation of oxycodone. Collegium also offers Nucynta products in extended-release and immediate-release formulations, along with Symproic for opioid-induced constipation. The company employs proprietary DETERx platform technology designed to maintain safety profiles while deterring abuse through various manipulation methods. Headquartered in Stoughton, Massachusetts, and founded in 2002, Collegium serves healthcare providers and patients across the United States, positioning itself as a leader in responsible pain management and ADHD treatment.

CEO Mr. Vikram Karnani · 357 employees · United States · https://www.collegiumpharma.com